New drugs must outrun JAKAFI’s cliff
- JAKAFI is still the main cash engine, with $757.8 million of Q1 2026 net sales.
- OPZELURA, NIKTIMVO, and ZYNYZ are helping widen the business beyond one lead drug.
- Povorcitinib looks much more important after positive Phase 3 vitiligo data and an accepted HS filing.
- The big bear case is the 2028 JAKAFI patent cliff and new patent fights around OPZELURA.
- A CMS rebate dispute tied to OPZELURA now carries a $245.9 million accrual.
A race before 2028
Incyte is in a stronger spot than it was a year ago, but the story is still a race. JAKAFI brings in most of the money today. Its U.S. patent protection is the key issue because exclusivity is expected to end in 2028.
The bull case is that Incyte is building enough new growth to soften that hit. OPZELURA is already a real dermatology business. NIKTIMVO and ZYNYZ are growing from newer launches. Povorcitinib, an oral JAK1 drug, became more important after positive Phase 3 data in vitiligo and FDA acceptance of the hidradenitis suppurativa filing.
The bear case is that the bridge is still not fully built. Patent fights are active for JAKAFI and OPZELURA. The OPZELURA CMS line extension rebate dispute has also grown into a direct money risk, with a $245.9 million accrual as of March 31, 2026.
Finn’s view is balanced. Incyte has strong execution and good financial health, but the market is right to ask whether the next wave of drugs can replace enough JAKAFI profit on time.
Drug sales plus partner royalties
Incyte discovers, develops, and sells prescription drugs. It focuses mainly on hematology and oncology, which means blood diseases and cancer, plus inflammation and autoimmunity, which includes skin disease.
Most of the business comes from direct product sales. In Q1 2026, total revenue was $1.2727 billion. JAKAFI net sales were $757.8 million, OPZELURA net product revenue was $143.0 million, NIKTIMVO net sales were $55.1 million, and ZYNYZ net sales were $41.4 million.
Incyte also gets royalty revenue from partners. Novartis sells JAKAVI outside the U.S., Lilly sells OLUMIANT, and Novartis sells TABRECTA. Total royalty revenue was $151.2 million in Q1 2026.
The model works best when patents keep copycat drugs away and payers cover the drugs at good prices. It breaks if generic competition arrives early, if reimbursement gets tougher, or if pipeline drugs miss key trials.
The drugs that matter
JAKAFI
JAKAFI is the anchor drug for myelofibrosis, polycythemia vera, and graft-versus-host disease. It produced $757.8 million of Q1 2026 net sales, so the 2028 patent cliff matters a lot.
OPZELURA
OPZELURA is a topical ruxolitinib cream for atopic dermatitis and vitiligo. Its label was expanded in September 2025 to include mild to moderate atopic dermatitis in children aged two and older.
Povorcitinib
Povorcitinib is the key pipeline swing factor. The FDA accepted its hidradenitis suppurativa filing in Q1 2026, and positive Phase 3 vitiligo data support filings planned for Q1 2027.
NIKTIMVO
NIKTIMVO launched in the U.S. in January 2025 for chronic graft-versus-host disease. It reached $55.1 million of Q1 2026 net sales, showing strong early uptake.
ZYNYZ
ZYNYZ is an immuno-oncology drug used in Merkel cell carcinoma. Q1 2026 net sales were $41.4 million, making it one of the newer products helping diversify revenue.
MONJUVI and MINJUVI
Tafasitamab is sold as MONJUVI or MINJUVI. Incyte now holds full global rights, and positive Phase 3 first-line DLBCL data could support a filing in 2026.
PEMAZYRE and ICLUSIG
These are smaller oncology products. They add breadth to the cancer portfolio, but they are not the center of the investment case.
Partnered royalties
Incyte earns royalties from drugs sold by partners, including JAKAVI, OLUMIANT, and TABRECTA. Royalty revenue was $151.2 million in Q1 2026.
Q1 revenue still centers on JAKAFI
This mix uses Incyte’s Q1 2026 revenue disclosure for the three months ended March 31, 2026. JAKAFI remains the largest piece, so product concentration is still the main caveat.
What could break the story
JAKAFI patent cliff
High impact · High oddsJAKAFI is the largest revenue source, with $757.8 million of Q1 2026 net sales. The key U.S. exclusivity issue is 2028, and several generic challengers remain active. If copycat drugs arrive sooner or take share faster than expected, Incyte’s cash flow could fall before new products are large enough.
OPZELURA rebate dispute
High impact · Medium oddsCMS may treat OPZELURA as a line extension of JAKAFI for Medicaid rebate purposes. Incyte had accrued $245.9 million for this issue as of March 31, 2026. The company said the impact on OPZELURA gross-to-net deductions for Q1 2026 was about 8.4%, which means this can directly hurt profitability.
OPZELURA generic challenges
High impact · Medium oddsOPZELURA is one of Incyte’s main growth drivers, but Padagis, Taro, Zydus, and Encube have filed ANDAs seeking approval for generic versions. ANDA means a generic drug application that can challenge patents. A loss or weak settlement would reduce the value of a key post-JAKAFI product.
Povorcitinib launch gap
Medium impact · Medium oddsPovorcitinib now looks more de-risked after positive Phase 3 vitiligo data and an accepted HS filing. But trial success does not guarantee approval, payer access, or fast adoption. If HS approval slips past Q1 2027 or vitiligo filings are delayed, the post-JAKAFI bridge gets weaker.
New product ramp disappoints
Medium impact · Medium oddsNIKTIMVO and ZYNYZ are growing, but they are still much smaller than JAKAFI. NIKTIMVO had $55.1 million of Q1 2026 net sales and ZYNYZ had $41.4 million. If their ramp slows, investors may question whether the portfolio is broad enough.
In one breath
What does Incyte do?
Incyte makes prescription drugs for cancer, blood diseases, and immune conditions. Its biggest drug is JAKAFI, while OPZELURA is its main dermatology growth product.
Why is JAKAFI so important to Incyte stock?
JAKAFI is the main cash generator, with $757.8 million of Q1 2026 net sales. The worry is that U.S. patent exclusivity is expected to end in 2028, which could bring generic competition.
What is the biggest upside catalyst for Incyte?
Povorcitinib is the biggest pipeline catalyst. It has an accepted FDA filing in hidradenitis suppurativa and positive Phase 3 data in vitiligo, with more regulatory steps expected through Q1 2027.
What is the OPZELURA CMS dispute?
CMS may classify OPZELURA as a line extension of JAKAFI for rebate rules. Incyte accrued $245.9 million for the issue as of March 31, 2026, so the outcome could affect OPZELURA profit.